Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 22, 2026PharmaceuticalsOpen Access

Advances in the Management of Pediatric Inflammatory Bowel Disease: From Biologics to Small Molecules

View Full Paper
Ask AI
Bookmark
Share

Authors

BMB. MucciEPElisabetta PalazzoloFRFlaminia Ruberti

Discussion

Loading...

Member takes

Overview

Narrative review summarizes efficacy and safety of biologics and small molecules in pediatric inflammatory bowel disease, suggesting new therapeutic options.

Key Points

  • This review aims to summarize advancements in managing pediatric inflammatory bowel disease through biologic and small-molecule therapies.
  • Literature search conducted across PubMed, Embase, and Cochrane Library.
  • Focused on studies published in the last five years.
  • Data retrieved from guidelines and position papers from relevant organizations.
  • Anti-TNF agents infliximab and adalimumab are effective for remission induction and maintenance.
  • New biologics like vedolizumab and ustekinumab show promise for patients not responding to anti-TNF treatment.
  • Emerging small molecules such as JAK inhibitors and S1P modulators provide rapid, oral treatment options.
  • The gut microbiome is noted as a potential therapeutic target influencing treatment efficacy.

Cite This Study

Mucci et al. (2026) studied this question.

synapsesocial.com/papers/6971be50642b1836717e2fa2https://doi.org/10.3390/ph19010176
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of vedolizumab and ustekinumab in pediatric‐onset inflammatory bowel disease: A real‐world multicenter study2024 · 5 citations
  2. 2Gut Microbiome as a Target of Intervention in Inflammatory Bowel Disease Pathogenesis and Therapy2024 · 32 citations
  3. 3Systematic review and meta‐analysis: opportunistic infections and malignancies during treatment with anti‐integrin antibodies in inflammatory bowel disease2015 · 81 citations
  4. 4Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease2014 · 1,091 citations
  5. 5Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease2016 · 125 citations